The first pharmaceutical for eosinophilic esophagitis approved in the U.S.

The U.S. Drug Administration has approved the drug Dupixent (dupilumab) to treat inflammation of the oesophagus of the type eosinophil esophagitis.

Uppgift: Sanofi planerar avknoppning av sina receptfria läkemedel

Den franska läkemedelsjätten Sanofi uppges ha bett ett antal banker att pitcha för att delta i att hantera företagets planerade avknoppning av sin OTC-verksamhe...

Stockholm aims at becoming one of the world’s top life science regions

Regional Chair for Finance, Irene Svenonius (M), believes that Stockholm can realise the goal of becoming one of the world’s top 5 regions in life science by 20...

Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far

Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, ...

Babypuderskandalen når Europa – första stämningen mot J&J i Storbritannien

De enorma skadeståndsprocesserna mot Johnson & Johnson, vars talkpuder påstås ha orsakat cancer, har nu även nått Storbritannien.

Neanderthal gene variants may cause Viking disease

A new study suggests that the so-called Viking disease, which affects the hand function in many older people, may be linked to gene variants inherited from Neanderthals.

The dock that “thinks” for itself

The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...

Galenica AB

"Are we doing business the wrong way around in the Life Science Sector?"

For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which...

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

Collaboration in laboratory automation

The Dutch company Synchron Lab Automation developed an automated DNA extraction system with high throughput, working very closely together with Festo. As a resu...

Gel mot håravfall lockar miljardinvestering

Det amerikanska bioteknikbolaget Pelage Pharmaceuticals väcker stort intresse med sin regenerativa kandidat mot ärftligt håravfall. Nu tar bolaget in 120 miljon...

SGS Fimko beviljas status som anmält organ enligt IVD-förordningen

Helsingfors, 21.10.2025 / SGS Fimko Oy har nått en betydande milstolpe i och med att den Europeiska kommissionen officiellt har utsett företaget till ett anmält...

Texas stämmer Tylenol-tillverkare – anklagas för att ha dolt påstådd autismkoppling

Texas justitieminister stämmer Johnson & Johnson och dess avknoppning Kenvue för att ha dolt misstänkta risker med smärtstillande läkemedlet Tylenol, kopplade t...

The new ZEISS Celldiscoverer 7 has been launched

Adaptable automation for advanced workflows.

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

CTC Clinical Trial Consultants AB

Galderma

Wusson Accelerator AB

Merck Life Science A/S

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Accurate removal of prostate tissue

Medical robots play an important role in diagnostics

KI-bolag får stöd av Michael J. Fox Foundation

Svenska Umecrine Cognition har fått ett anslag från The Michael J. Fox Foundation för att utvärdera bolagets läkemedelskandidat golexanolon som behandling för P...

The Swedish Life Science Office: “We lost in both coordination and manpower”

Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Depart...